《新股消息》傳亞盛醫藥已通過上市聆訊最快本月啟動招股
據市場消息稱,專注全球創新的1類新藥研發企業亞盛醫藥已於日前通過港交所(00388.HK)上市聆訊,最快於本月底展開上市前推介及啟動公開招股,擬於7月掛牌上市,有望成為原創小分子1類新藥第一股。是次上市聯席保薦人為美銀美林及花旗。
據亞盛醫藥上市文件,該公司旨在解決尚未滿足、無藥可醫的臨床需求,現已有8款原創1類新藥進入臨床階段,目前正在中國、美國及澳洲進行20項I期或II期臨床試驗。其產品管線包括靶向細胞凋亡路徑關鍵蛋白的抑制劑、新一代酪氨酸激(酉每)抑制劑等。公司核心產品HQP1351為針對格列衛耐藥的第三代產品,已進入關鍵註冊臨床II期試驗,有望通過臨床二期結果即申請上市。(el/ca) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.